Melanoma survivors: new study tracks immunotherapy side effects
NCT ID NCT04990726
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 126 melanoma survivors who are receiving immunotherapy after surgery. Researchers will track side effects and quality of life for up to 24 months. They will also collect blood samples to look for markers that might predict who gets side effects. The goal is to better understand and manage these side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better predict and manage immunotherapy side effects in melanoma survivors, improving quality of life.
- What could go wrong
- This is an observational study, not a treatment trial. It may not find clear links between side effects and blood markers, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- Two-Drug combo targets Hard-to-Treat melanoma
- Can interferon keep melanoma from coming back after surgery?
- Wheat germ supplement studied for immune boost in advanced cancer
- Pee power: urine bacteria may predict melanoma treatment success